Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560879 | 0.76 | NPC1 (0.59) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7267356 | 0.72 | KMT2A (0.45) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7267353 | 0.72 | KMT2A (0.45) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL11774241 | 0.70 | GRIN2D (0.70) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL11774250 | 0.70 | GRIN2D (0.70) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL22198272 | 0.70 | GRIN2D (0.70) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL13561062 | 0.70 | CYP19A1 (0.69) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12416591 | 0.69 | CYP1A2 (0.61) | KDM4ENPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL16274602 | 0.69 | CYP1A2 (0.61) | KDM4ENPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL6582867 | 0.69 | ALDH1A1 (0.64) | KDM4ENPC1RAB9ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | SCARB1, MSR1, HAVCR2 | KDM4E 4698/4885NPC1 111/4885RAB9A 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.